TENAX THERAPEUTICS, INC.·4/A

Nov 20, 6:16 PM ET

Almenoff June Sherie 4/A

4/A · TENAX THERAPEUTICS, INC. · Filed Nov 20, 2025

Insider Transaction Report

Form 4/AAmended
Period: 2025-11-17
Transactions
  • Purchase

    Common Stock

    2025-11-18$7.52/sh+1,900$14,2801,993 total(indirect: By LLC)
  • Purchase

    Common Stock

    2025-11-17$7.15/sh+93$66593 total(indirect: By LLC)
Footnotes (2)
  • [F1]The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
  • [F2]This transaction was executed in multiple trades at prices ranging from $7.45 to $7.70. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Documents

1 file
  • 4
    primary_doc.xml

    PRIMARY DOCUMENT